Effects of neoadjuvant chemotherapy vs chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis

Table 2 Characteristic of the neoadjuvant regimen, n (%)

Ref.	nCT	nCRT
	Chemotherapy	Chemotherapy	Irradiation
Stahl et al[44], 2017	15 × weekly CFFa	15 × weekly CFFa followed by 3 wk course of CRT + 1 cycle CE	30 Gy in 15 fractions of 2 Gy in 3 wk
Burmeister et al[43], 2011	C (80 mg/m2) + iv 5-FU (1000 mg/m2/d) on days 1 and 21	CF + RT, 5-FU reduced to 800 mg/m2/d (on day 21)	35 Gy in 15 fractions in 3 wk (on day 21)
Visser et al[42], 2018	OEO2	OEO2 + RT	35 Gy in 15 fractions or 45 Gy in 25 fractions
	MAGIC	DCF (2 cycles pre-operatively) + RT	45 Gy in 25 fractions
	DCF (2 cycles pre-operatively)	CROSS (since 2015)	41.4 Gy in 23 fractions of 1.8 Gy in 5 wk
	Cisplatin + 5-FU: 92 (70)	Cisplatin + 5-FU: 94 (72)	35 Gy: 69 (53)
	Epirubicin, cisplatin, 5-FU: 30 (23)	Epirubicin, cisplatin, 5-FU: 2 (2)	41 Gy: 14 (11)
	Carboplatin + paclitaxel: 0 (0)	Carboplatin + paclitaxel: 20 (15)	45 Gy: 40 (31)
	Other: 9 (7)	Other: 15 (11)	Other: 8 (6)
Markar et al[41], 2017	mainly MAGIC, OEO2 or OEO5 regimens[8,10,45]	CROSS regimen[7,46]	41.4 Gy in 23 fractions of 1.8 Gy in 5 wk
Goense et al[40], 2017	ECX	CROSS regimen[7,46]	41.4 Gy in 23 fractions of 1.8 Gy in 5 wk
Favi et al[39] , 2017	FLOT[47]	CROSS regimen[7,46]	41.4 Gy in 23 fractions of 1.8 Gy in 5 wk
Anderegg et al[35], 2017	ECX	CROSS regimen[7,46]	41.4 Gy in 23 fractions of 1.8 Gy in 5 wk
Spicer et al[38], 2016	Cornell: Platinum or taxane-based doublet, or both	concurrent ChT + RT	50.4 Gy
	McGill: DCF (3 cycles)[48]
Luc et al[36], 2015	DCF (3 cycles pre- and postoperatively)	continuous iv 5-FU 750 mg/m2/d on days 1–5 by, C 20 mg/m2 on day 1	45 Gy for 5 d per week at 1.8 Gy/d (started on day 28 along with the second CT cycle)
Münch et al[37], 2018	N/A	N/A	N/A

OEO2: Two cycles of cisplatin and 5-fluoruracil (5-FU). OEO5: Five cycles of cisplatin and 5-FU. CFFa: 15 × weekly 5-FU (2000 mg/m², 24 h infusion)/Fa (500 mg/m², 2 h infusion) and biweekly cisplatin (50 mg/m², 1 h infusion), in 14 wk. MAGIC: Protocol epirubicin, cisplatin, and 5-FU for three cycles before andthree cycles after esophagectomy (EGJ Siewert II EAC and good vital status). DCF: Docetaxel 75 mg/m² (on day 1), cisplatin 75 mg/m² (on day 1), and 5-FU 750 mg/m²/d by continuous infusion on days 2–5, (day 1 = day 22 = day 43). CROSS: With concurrent weekly administration of carboplatin (targeted at an area under the curve of 2 mg/mL per min) and paclitaxel (50 mg/m² of body-surface area). Forty-one four Gy in 23 fractions of 1.8 Gy in 5 wk. FLOT: 5-FU/leucovorin, oxaliplatin, and docetaxel 50 mg/m² every 2 wk. ECX: Pre- and postoperative 3-wk cycles epirubicin (50 mg/m²) and cisplatin (60 mg/m²), followed by 1000 mg/m² of capecitabine twice daily for 14 d or 625 mg/m² of capecitabine twice daily for 21 d. Adaptations to the regimen such as dose reduction or change of regimen to oxaliplatin or 5-FU were applied when necessary. C: Cisplatin; F: Fluorouracil; P: Paclitaxel; Fa: Folinic acid; E: Etoposide; N/A: Not applicable; nCT: Neoadjuvant chemotherapy; nCRT: Neoadjuvant chemoradiotherapy; AC: Adenocarcinoma; CRT: Chemoradiotherapy; CT: Chemotherapy; RT: Radiotherapy; 5-FU: 5-fluoruracil.